University of California, Los Angeles
Welcome,         Profile    Billing    Logout  
 671 Trials 
1415 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Buyon, Jill
NCT04474223: Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

Recruiting
3
1300
Canada, US
Dexamethasone, IVIG
NYU Langone Health
AVB - Atrioventricular Block, Fetal AVB
08/26
10/26
SHIELD, NCT05799378: Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

Recruiting
3
330
US
Hydroxychloroquine, Placebo
NYU Langone Health, National Institutes of Health (NIH)
Systemic Lupus Erythematosus
12/28
06/29
NCT00074373: The Research Registry for Neonatal Lupus

Completed
N/A
100
US
No intervention; observational, The study is observational
NYU Langone Health
Neonatal Lupus, Systemic Lupus Erythematosus, Sjogren's Syndrome, Congenital Heart Block
06/16
06/16
PROMISSE, NCT00198068: Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

Recruiting
N/A
700
Europe, Canada, US
Hospital for Special Surgery, New York, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Lupus Erythematosus, Antiphospholipid Syndrome
03/25
03/25
Currier, Judith
CLEAR HIV, NCT05488431: Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial ( Trial)

Recruiting
2
121
US
Bempedoic acid, BA, Placebo
Priscilla Hsue, MD, University of California, Los Angeles, Massachusetts General Hospital
Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis
03/28
03/28
Stek, Alice
NCT06082453: Modernizing Perinatal Syphilis Testing

Recruiting
N/A
924
US
Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum, Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum, Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis
The University of Texas Health Science Center, Houston, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Syphilis
11/27
11/27
Ganz, Patricia A
NCT03025139: Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)

Active, not recruiting
3
96
US
Educational Intervention, Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational, Laboratory Biomarker Analysis, Meditation Therapy, Meditation, Questionnaire Administration
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Cancer Survivor, Early-Stage Breast Carcinoma, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
02/23
02/24
NCT04705025: Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer

Terminated
2
5
US
Cognitive Behavior Therapy, CBT, cognitive therapy, CT, Interview, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Jonsson Comprehensive Cancer Center, Blue Note Therapeutics
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
03/23
03/23
NCT04290897: Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors

Recruiting
2
24
US
Anhydrous Enol-oxaloacetate, Questionnaire Administration
Jonsson Comprehensive Cancer Center, Breast Cancer Research Foundation, MetVital, Inc.
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
11/25
11/26
NCT04593277: Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study

Active, not recruiting
N/A
556
US
Internet Mobile Technology, www-mobile, Internet-Based Intervention, Questionnaire Administration, Supportive Care, Supportive Therapy, Symptom Management, Therapy, Supportive, Informational Intervention
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Malignant Neoplasm, Leukemia, Lymphoma, Malignant Solid Neoplasm, Sarcoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Thyroid Gland Carcinoma
12/25
12/25
NRG-CC011, NCT05896189: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Recruiting
N/A
386
US
Arm 1: Computerized Cognitive Training-Global Stimulation Games, Arm 2: Computerized Cognitive Training-Neuroplasticity Games
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer, Cognitive Impairments
02/27
11/27
Salusky, Isidro B
FIT4KID, NCT04741646: Ferric Citrate and Chronic Kidney Disease in Children

Recruiting
2
160
Canada, US
Ferric Citrate, Auryxia, Placebo
University of California, Los Angeles, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Diseases
12/25
12/25
Dobkin, Bruce
NCT02093624: A Phase II Trial of Rituximab In Myasthenia Gravis

Not yet recruiting
2
50
US
Rituximab, Placebo
Yale University
Myasthenia Gravis
05/17
12/17
CAMAROS, NCT04789616: The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke

Recruiting
2
120
Canada
Maraviroc, Celsentri, Exercise Program, Placebo, "Sugar" Pill, Activity Sensor, Motor Learning
University of Calgary, University Health Network, Toronto, University of California, Los Angeles, Sunnybrook Health Sciences Centre, University of British Columbia, Memorial University of Newfoundland, Dalhousie University, Parkwood Hospital, London, Ontario, Riverview Health Centre Foundation, The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Stroke
12/25
12/25
Schiller, Gary J
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Exclusivity expiry in US
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT06401356: An Extension Study for Patients Previously Enrolled in Studies with Pelabresib

Recruiting
3
50
Europe, US
Pelabresib, CPI-0610
Constellation Pharmaceuticals
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
06/29
06/29
NCT04260698: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Active, not recruiting
3
36
US
omidubicel, NiCord
Gamida Cell ltd
Hematological Malignancies
05/25
05/25
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
BP1001-201-AML, NCT02781883: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Recruiting
2a
108
US
BP1001 in combination with Ventoclax plus decitabine, Liposomal Grb-2, L-Grb-2, BP1001 plus decitabine
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia (AML)
12/24
12/24
NCT04231851: CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Active, not recruiting
2
30
US
Glasdegib, DAURISMO™, CPX-351, Daunorubicin and cytarabine, VYXEOS®
University of California, Irvine, Jazz Pharmaceuticals, Pfizer
Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
06/25
06/27
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting
2
76
US, RoW
Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza
Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
02/28
02/30
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001)

Active, not recruiting
2
25
US
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network
Sickle Cell Disease
05/26
05/26
Beat AML, NCT03013998: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from Beat AML trial for acute myeloid leukemia
Recruiting
1/2
2000
US
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Enasidenib, Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), GS-9973, ENTO, Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), TAK-924, MLN4924, Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21)
Beat AML, LLC
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
12/26
12/26
KCP-8602-801, NCT02649790 / 2021-003810-38: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Active, not recruiting
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc, Karyopharm Therapeutics Inc.
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Hourglass Jan 2024 - Dec 2024 : Top-line data from cohort 6 for 1L BPCDN
Active, not recruiting
1/2
179
Europe, US
IMGN632
AbbVie
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
09/23
12/26
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
OPAL, NCT04329728: The Study: AVM0703 for Treatment of Lymphoid Malignancies

Recruiting
1/2
144
US
AVM0703, Supra-Pharmacologic Dexamethasone Phosphate
AVM Biotechnology Inc, Medpace, Inc.
Lymphoid Malignancies
04/25
06/25
NCT04774536: Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease

Recruiting
1/2
9
US
CRISPR_SCD001
Mark Walters, MD, University of California, Los Angeles, University of California, Berkeley
Sickle Cell Disease
03/27
03/29
NCT02247843: Stem Cell Gene Therapy for Sickle Cell Disease

Active, not recruiting
1/2
4
US
βAS3-FB vector transduced peripheral blood CD34+ cells, Lenti/βAS3-FB
Donald B. Kohn, M.D., California Institute for Regenerative Medicine (CIRM)
Sickle Cell Disease
12/25
12/25
NCT04536792: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Completed
1
122
Europe, US
AG-946, AG-946 Matched Placebo
Agios Pharmaceuticals, Inc.
Healthy Volunteers, Anemia, Sickle Cell
12/23
12/23
BP1002-102-AML, NCT05190471: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Recruiting
1
48
US
BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Liposomal Bcl-2; L-Bcl-2, Decitabine (in combination with BP1002), Decitabine
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
03/24
09/24
SENTI-202-101, NCT06325748: SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Recruiting
1
21
US, RoW
SENTI-202, Fludarabine, Cytarabine (ara-C)
Senti Biosciences
AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
09/25
08/40
NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
US
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
CLN-049-001, NCT05143996: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
1
60
US
CLN-049
Cullinan Oncology Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
08/25
11/25
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
McCracken, James
ACEP4, NCT03243552: Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD

Active, not recruiting
2
56
US
L-DOPA versus Placebo, Social Skills Training, PEERS
University of California, Los Angeles, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ASD
12/23
12/23
Glaspy, John A
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
NCT00039247: Darbepoetin Alfa in Treating Anemia in Patients With Cancer Who Are Receiving Chemotherapy

Active, not recruiting
2
NA
darbepoetin alfa
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anemia, Unspecified Adult Solid Tumor, Protocol Specific
 
 
NCT04712851: Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Recruiting
2
25
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Jonsson Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
01/25
01/26
Glaspy BMS CA209-9ET Breast, NCT04185311: Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Terminated
1
6
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, HER2/Neu Negative, Invasive Ductal Carcinoma, Not Otherwise Specified, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
05/23
05/23
NCT00090935: Epoetin Alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy

Active, not recruiting
N/A
US
epoetin alfa
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
 
 
Cloughesy, Timothy F
NCI-2018-02010, NCT03732352: 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Completed
2
12
US
Fludeoxyglucose F-18, 18FDG, FDG, fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Osimertinib, AZD-9291, AZD9291, Mereletinib, Tagrisso, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Jonsson Comprehensive Cancer Center, AstraZeneca
EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, TP53 Wt Allele
01/24
01/24
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT05664243: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
4
US
Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
In8bio Inc.
Glioblastoma
12/25
12/25
NCT02101905: Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Completed
1
29
US
Laboratory Biomarker Analysis, Lapatinib, GSK572016, GW 2016, GW 572016, GW-572016, GW2016, GW572016, Lapatinib Ditosylate, Tykerb, Pharmacological Study, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
10/21
10/24
NCT04201873: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Recruiting
1
40
US
Dendritic Cell Tumor Cell Lysate Vaccine, DC tumor cell lysate vaccine, dendritic cell-pulsed tumor cell lysate vaccine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Placebo Administration, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI), Merck Sharp & Dohme LLC, Phase One Foundation, Oncovir, Inc.
Recurrent Glioblastoma
08/25
08/26
Aronson, William
NCT05820724: PSMA PET Scan and mpMRI for Prostate Cancer Detection

Not yet recruiting
2
100
US
PSMA PET scan, DCFPyL PET/CT imaging, No PSMA PET, 18F- DCFPyl Injection, DCFPyl
VA Greater Los Angeles Healthcare System, Lantheus Medical Imaging
Prostate Cancer Diagnosis
05/26
05/26
NCT00836615: Low-Fat Diet and Omega-Fatty Acids for Prostate Cancer Prevention

Active, not recruiting
N/A
70
US
Western Diet, Diet created by General Clinical Research Center., Low-fat diet, Fish oil capsules: 1 g by Pharmavite Inc, Mission Hills, CA
University of California, Los Angeles, National Cancer Institute (NCI)
Prostate Cancer
12/11
12/11
NCT02176902: Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

Active, not recruiting
N/A
107
US
behavioral dietary intervention, omega-3 fatty acid, fish oil, n-3 fatty acid, O3FA, laboratory biomarker analysis
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI), Pharmavite LLC, Seafood Industry Research Fund
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
11/25
11/26
Shoptaw, Steve
STAR-OM, NCT04706624: Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics

Active, not recruiting
N/A
667
RoW
High intensity contingency management, Low intensity contingency management, SMS reminders, Matrix only, Matrix + Contingency management
Hanoi Medical University, University of California, Los Angeles, University of Medicine and Pharmacy at Ho Chi Minh City
Methamphetamine Abuse, Opioid-use Disorder, HIV Seropositivity
06/24
03/25
Chang, Eric L
NCT04305743: Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

Recruiting
4
60
US
OnabotulinumtoxinA 100 UNT, BOTOX
University of South Florida, Medstar Health Research Institute
Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
01/21
06/21
GESTALT, NCT05342883: GammaTile and Stupp in Newly Diagnosed GBM

Recruiting
4
61
US
Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)
GT Medical Technologies, Inc.
Glioblastoma
07/27
12/27
NCT04114981: Single Fraction Stereotactic Radiosurgery Compared with Fractionated Stereotactic Radiosurgery in Treating Patients with Resected Metastatic Brain Disease

Active, not recruiting
3
242
Canada, US
Single Fraction Stereotactic Radiosurgery, Stereotactic Radiosurgery, Fractionated Stereotactic Radiosurgery, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain
03/26
03/28
NRG-BN003, NCT03180268: Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Recruiting
3
148
Canada, Japan, US, RoW
Clinical Observation, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
NRG Oncology, National Cancer Institute (NCI)
Grade II Meningioma, Intracranial Meningioma
06/27
08/27
NCT04725838: Differential Target Multiplexed Spinal Cord Stimulation (DTM-SCS®) Real World Outcomes

Completed
N/A
255
US
Medtronic Intellis™ and Vanta™
Celéri Health, Inc., Medtronic
Chronic Pain
07/23
07/23
Pantuck, Allan
NCT04305925: Focal Laser Ablation of Prostate Cancer

Active, not recruiting
1
10
US
Focal Laser Ablation
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Prostate Cancer
01/23
10/25
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32
Perlman, Susan
NEAT, NCT06193200: Evaluate the Neurological Effects of EryDex on Subjects With A-T

Recruiting
3
106
Europe, US
Dexamethasone sodium phosphate, DSP, Placebo
Quince Therapeutics S.p.A., Biotrial
Ataxia Telangiectasia
08/25
09/25
OLE_NEAT, NCT06664853: Open-Label Extension of EryDex Study IEDAT-04-2022

Recruiting
3
106
Europe, US
Dexamethasone sodium phosphate
Quince Therapeutics S.p.A., Biotrial
Ataxia Telangiectasia
11/26
11/26
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Terminated
2/3
23
Europe, US, RoW
SLS-005, Placebo
Seelos Therapeutics, Inc.
Spinocerebellar Ataxia Type 3
11/23
11/23
NCT03759678 / 2018-004407-39: N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

Recruiting
2
39
Europe, US
IB1001, N-Acetyl-L-Leucine
IntraBio Inc
Ataxia Telangiectasia, Louis Bar Syndrome
12/24
03/25
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy

Active, not recruiting
2
159
Europe, Japan, US
TAK-341, MEDI1341, Placebo
Takeda, AstraZeneca
Multiple System Atrophy
07/25
07/25
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Recruiting
2
80
US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
NCT03487367: Clinical Trial Readiness for SCA1 and SCA3

Active, not recruiting
N/A
200
US
The Methodist Hospital Research Institute, University of Michigan, University of Minnesota, University of Utah, University of California, Los Angeles, University of Chicago, University of South Florida, Harvard University, Johns Hopkins University, University of Florida, Columbia University, Emory University, University of California, San Francisco, University of Alabama at Birmingham, University of Colorado, Denver, University of Rochester, Stanford University, Northwestern University, German Center for Neurodegenerative Diseases (DZNE), Institut de Recherche sur la Moelle épinière et l'Encéphale, University of Pennsylvania, Ohio State University, University of Iowa
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia 3
12/23
12/23
NCT06445712: Examining the Role of Pain in the Link Between Early Childhood Adversity and Psychopathology

Recruiting
N/A
40
US
Parental Support Cold Pressor Task
Washington University School of Medicine, National Center for Advancing Translational Sciences (NCATS)
Child Development
04/25
04/25
NCT01060371: Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Recruiting
N/A
800
US
All Participants
University of Florida, National Ataxia Foundation, University of California, Los Angeles
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6
05/24
05/24
IDEA, NCT04268147: Instrumented Data Exchange for Ataxia Study

Completed
N/A
128
US
University of Chicago, Pfizer, Biogen, APDM Wearable Technologies
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Friedreich Ataxia
04/24
06/24
NCT06623890: A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it for the First Time

Recruiting
N/A
300
Europe, US, RoW
Omaveloxolone, SKYCLARYS, BIIB141
Reata, a wholly owned subsidiary of Biogen
Friedreich Ataxia
10/29
10/29
FA-COMS, NCT03090789: FA Clinical Outcome Measures

Active, not recruiting
N/A
2000
Canada, US, RoW
Friedreich's Ataxia Research Alliance, University of Rochester, Children's Hospital of Philadelphia
Friedreich Ataxia, Neuro-Degenerative Disease
01/30
01/30
UNIFAI, NCT06016946: Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

Recruiting
N/A
3000
Europe, Canada, US, RoW
Friedreich's Ataxia Research Alliance
Friedreich Ataxia
01/48
01/48
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62
Buchanan, Robert W
TrypNAC-II, NCT04013555: The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia

Completed
1/2
88
US
N-acetylcysteine (NAC), Cetylev, Placebo, Tryptophan
University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
08/24
08/24
ModSoCCS, NCT04418011: Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum Disorders

Completed
N/A
70
Canada, US
Repetitive Transcranial Magnetic Stimulation, Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation), Repetitive Transcranial Magnetic Stimulation (Sham)
Centre for Addiction and Mental Health, The Feinstein Institutes for Medical Research, University of Maryland School of Medicine, National Institutes of Health (NIH)
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
02/23
02/23
NCT03622905: ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

Completed
N/A
74
Europe, Canada, US
DBS-f On, DBS Off
Functional Neuromodulation Ltd
Alzheimer Disease
02/24
02/24
NCT05204407: Luteolin for the Treatment of People With Schizophrenia

Recruiting
N/A
60
US
Luteolin, PureLut, Placebo
University of Maryland, Baltimore, University of California, Los Angeles, Stanley Medical Research Institute
Schizophrenia, Schizoaffective Disorder
03/25
03/25
FOCIS, NCT05527210: Prebiotic Treatment in People With Schizophrenia

Recruiting
N/A
60
US
Prebiotic, Prebiotin®, Placebo Prebiotic, maltodextrin
University of Maryland, Baltimore, National Center for Complementary and Integrative Health (NCCIH)
Schizophrenia, Schizoaffective Disorder
01/26
01/26
Saver, Jeffrey
BRIDGE-TNK, NCT04733742: Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke

Recruiting
2/3
544
RoW
rhTNK-tPA, TNKase, TNK-tPA, Endovascular treatment, intra-arterial treatment, interventional therapy
Xinqiao Hospital of Chongqing, CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD
Stroke, Acute, Stroke, Ischemic
12/25
03/26
SEACOAST, NCT03737786: 1- SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke

Recruiting
2b
90
US
Tight control of end-tidal CO2 levels
University of California, Los Angeles, University of Southern California
Acute Stroke
01/25
01/25
EMAGINE, NCT05044507: The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "" STUDY)

Completed
N/A
100
US
BQ 2.0, BQ 2.0 sham stimulation group, BQ 2.0 active stimulation group
BrainQ Technologies Ltd.
Ischemic Stroke
11/23
01/24
NCT06386874: EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment

Recruiting
N/A
122
US
Q Therapeutic System (BQ 3.0) - Sham, BQ 3.0 Sham Stimulation Group, Q Therapeutic System (BQ 3.0) - Active, BQ 3.0 Active Stimulation Group Interventions
BrainQ Technologies Ltd.
Ischemic Stroke
07/26
10/26
TESTED, NCT05911568: Treatment With Endovascular Intervention for STroke Patients With Existing Disability

Recruiting
N/A
1060
US
Endovascular Stroke Treatment, Medical Management
University of Cincinnati, Patient-Centered Outcomes Research Institute, University of California, Los Angeles, Icahn School of Medicine at Mount Sinai
Stroke, Stroke, Acute, Stroke, Ischemic
01/28
04/28
Kasari, Connie
NCT03205475: JASPER Implementation in NFLD

Completed
N/A
27
Canada
Alternate Coaching and Video Feedback Phase 1, Weekly Coaching in Phase 1, Weekly Coaching plus Intensive Refresher Course Phase 2, Weekly Coaching plus Peer Coaching Phase 2, Video Feedback Only Phase 2
Government of Newfoundland and Labrador
Autism Spectrum Disorder
12/18
12/23
EBJ, NCT04146428: Evaluating BOSCC and ELSA as Outcome Measures in the Context of a JASPER Intervention Trial

Recruiting
N/A
90
US
clinician-mediated JASPER, parent-mediated JASPER
University of California, Los Angeles, Simons Foundation
Autism Spectrum Disorder
01/25
08/25
TRAIN, NCT04698538: TSC Remote Assessment and Intervention

Completed
N/A
54
US
JASPER
University of California, Los Angeles
TSC
08/24
10/24
BLOOM, NCT04218331: Boosting Language Outcomes of Minimally Verbal Children With ASD

Recruiting
N/A
80
US
JASPER, PROMPT
University of California, Los Angeles, National Institutes of Health (NIH)
Autism Spectrum Disorder
06/25
06/25
NCT03883139: PRISM Intervention Study

Recruiting
N/A
140
US
JASPER, DTT (Discrete Trial Training)
University of California, Los Angeles
Autism Spectrum Disorder
03/25
03/26
PETAL, NCT05853861: Promoting Early Intervention Timing and Attention to Language

Recruiting
N/A
140
US
JASPER, Babble Bootcamp
University of California, Los Angeles, University of Massachusetts, Worcester
MONITOR, COACH
12/27
06/28
Vos, Sven De
NCT04212013: A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Active, not recruiting
3
23
US
Ibrutinib, Rituximab, Placebo
Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC.
Marginal Zone Lymphoma
03/27
03/27
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
NCT00124631: Suberoylanilide Hydroxamic Acid in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Active, not recruiting
2
50
US
vorinostat
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Lymphoma
 
 
NCT06810778: Duvelisib and Venetoclax in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Not yet recruiting
1/2
12
US
Duvelisib, Venetoclax
Jonsson Comprehensive Cancer Center
T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory
03/30
03/31
Ribas, Antoni
SWOG-S1221, NCT01902173: Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Completed
1/2
27
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel, Spexotras, Uprosertib, GSK2141795, Oral Akt Inhibitor GSK2141795
National Cancer Institute (NCI), GlaxoSmithKline, Novartis Pharmaceuticals
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
05/18
12/23
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT04119024: Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Recruiting
1
18
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, IL13 [EQ]BBzeta/truncated CD19[t]+ Naive and Memory T Cells, IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM Cells, IL13Ra2-specific-hinge-optimized-4-1BB-CAR/truncated CD19-expressing Autologous TN/MEM Lymphocytes, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Jonsson Comprehensive Cancer Center, Parker Institute for Cancer Immunotherapy, City of Hope National Medical Center, Melanoma Research Alliance, California Institute for Regenerative Medicine (CIRM)
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC V8, Pathologic Stage IV Cutaneous Melanoma AJCC V8, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Uveal Melanoma, Acral Melanoma, Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Pancreatic Neuroendocrine Tumor, Thyroid Cancer, Breast Cancer, Lung Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
10/25
10/26
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
 

Download Options